Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $31
HC Wainwright & Co. analyst Michael King maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $25 to $31.
HC Wainwright & Co. Initiates Coverage On Cogent Biosciences with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Michael King initiates coverage on Cogent Biosciences (NASDAQ:COGT) with a Buy rating and announces Price Target of $25.
Cogent Biosciences Q2 EPS $(0.43)
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.43) per share.
Cogent Biosciences Sponsored Study Titled ‘(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis’ Posted To ClinicalTrials.Gov; Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT04996875
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Cogent Biosciences Granted Orphan Designation For 3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5- carboxamide
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=827121